8210 Others - Milton Keynes Formulary

• Home
• Chapters
  • 1. Gastro-Intestinal System
  • 2. Cardiovascular system
  • 3. Respiratory System
  • 4. Nervous System
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary-tract Disorders
  • 8. Immune System and Malignant Disease
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Diseases
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological Products and Vaccines
  • 15. Anaesthesia
  • 16 Wound Management
  • 17. Miscellaneous Preparations
• Drugs
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
• MK Prescribing Advisory Group (MKPAG)
  • Application Forms
  • MKPAG Ratified Minutes
  • MKPAG Meeting Dates
  • Terms of Reference (ToR)
  • M&TC Minutes
• NICE Adherence Checklist
• GP Prescribing Group
  • Terms of reference
  • Minutes
  • Archived Minutes
• Shared Care Guidelines
• Local & National General Prescribing Information
  • 1. Financial and clinical responsibility for prescribing non-formulary drugs
  • 2. Repeat Prescribing Code of Practice
  • 3. When not to prescribe generically
  • 4. MK CCG Commissioning Policies
  • 5. Borderline Substances (ACBS)
  • 6. Selective List Scheme (SLS)
  • 7. Overseas visitors
  • 8. Travelling abroad
  • 9. Liquid Specials
  • 10. SPS Drug Monitoring Document Oct 2017
  • 11. Medication Information in Practices-November 2017
  • 12. Drugs That Prolong QT Interval
  • 13 Consultation Letter to Schools Nurseries-June 2017
  • 14 Letter to parents re changes in prescribing
  • 15. Self-Care Medicine List
• Biosimilar Position Statement
• Unlicensed Medicines
• Copyright Notice
• Patient Information Leaflets (New)
• About the Formulary Local Decisions
  • About the Joint Formulary
  • Format of the Formulary and Traffic Light Classification
• Newsletters
• Useful Links
• Contact Us

8.2.10 Others

Others

Malignant disease and immunosuppression

Lutetium (¹⁷⁷Lu) oxodotreotide (Lutathera®)

• Injection for Intravenous Infusion

Notes:

• Use as per NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (Aug 2018) 

Axicabtagene ciloleucel

• Single‑dose intravenous infusion

Notes:

• Use as per NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (Jan 2019)

Return to Chapter: 8. Immune System and Malignant Disease

Last updated by: Sheila Wood on 18-04-2019 11:45